Advertisement

Topics

Companies Related to "A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes" [Most Relevant Company Matches] RSS

20:22 EST 20th February 2019 | BioPortfolio

Here are the most relevant search results for "A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes" found in our extensive corporate database of over 50,000 company records.

Showing "Study SIMPONI Arrest Beta cell Loss Type Diabetes" Companies 1–25 of 2,900+

Extremely Relevant

Betagenon AB

Betagenon has secured a strong, proprietary technology platform based upon the extensive research expertise on type 2 diabetes disease mechanisms established by the Founders, leading experts in the field. Betagenon's vision is to become a frontier company that delivers new smart drug platform solutions to the pharmaceutical industry for treatment of the metabolic syndrome and diabetes type 2. Afte...


ImmunoMolecular Therapeutics

IM Therapeutics is developing personalized immuno-therapeutic drugs for autoimmune diseases based on the genetic risk attributed by human leukocyte antigen genes. The lead candidate drug is an oral small molecule that starves the autoimmune process in type 1 diabetes by blocking DQ8 on specific immune cells. Our goal is to preserve pancreatic beta cell fun...

Semma Therapeutics

Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients. Recent work in the laboratory of Professor Douglas Melton led to the discovery of a method to generate billions of functional, insulin-producing beta cells in the laboratory. This breakthrough technology has been exclusively licensed to Semma Therapeutics for t...


VivoScript, Inc.

Based in Orange County, California, VivoScript is an emerging biotech company established to commercialize a disruptive innovation in regenerative medicine. The new technology platform is named In Vivo Cell Reprogramming, or IVR. Using a combination of protein drugs, we can convert or reprogram one type of cells (substrate cells) to another type of cells (...

Diamyd Medical AB (publ)

The purpose of the GAD65-based diabetes therapy Diamyd(R) is to prevent, delay, or stop the autoimmune attack on beta cells in type 1 diabetes and other forms of autoimmune diabetes, thereby preserving the body's capacity to regulate blood sugar. This reduces the risk for both acute and long term diabetes complications significantly.

Opexa Therapeutics

Opexa Therapeutics is a commercialization driven biotechnology cellular therapy company that develops autologous personalized cell therapies for the treatment of various diseases. The Company is focused on its proprietary stem cell and T-cell technologies for the autologous use of peripheral blood derived adult stem cells in regenerative medicine as well as T cells for the treatment of autoimmune ...

Beta-Cell

Beta-Cell is engaged in the development and commercialisation of innovative cell and drug therapies for the treatment of diabetes. The primary therapeutic focus of the company is on beta-cells, the highly specialized endocrine cells located in pancreatic islets and responsible for producing insulin. Beta-Cell has an advanced pre-clinical xeno-transplantation program based on its proprietary techno...

Relevant

Novocell, Inc.

Novocell is a preclinical therapeutic company focused on diabetes. Our therapy is based on the encapsulation and implantation of pancreatic beta cell progenitors (Pro-Islet-1) derived from human stem cells which secrete insulin in patients. Our goal is that Pro-Islet-1 can free both Type 1 and Type 2 diabetic patients from insulin dependence on a long term basis, while reducing or eliminating hy...

Diamyd Medical AB

Founded in 1996, Diamyd Medical AB (OMXS: DIAM B) (OTCBB: DMYDY), is an emerging and global biotechnology company based in Stockholm, Sweden and Pittsburgh, PA, USA. Diamyd Medical is focused on developing treatments for diabetes, both Type 1 and Type 2, via GAD protein therapy. Its lead drug candidate, Diamyd™, is designed to reduce the need of insulin injections and prevent the destruction of ...

Tau Therapeutics LLC

Tau Therapeutics is a clinical stage company developing oncology drugs for solid tumors that selectively inhibit the T-type calcium channel – a novel mechanism of action for cancer. The company’s approach, called Interlaced Therapy™, capitalizes on the central role of calcium influx through T-type calcium channels during cancer cell growth. T-type ...

Diasome Pharmaceuticals, Inc.

Diasome Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. Based on more than thirty years of research and development in the fields of cell receptor targeting, insulin formulation, and hepatic (liver) glucose metabolism, the companyâ€...

Team Type 1 Foundation

Established in 2013, the Team Type 1 Foundation is a nonprofit organization pursuing a mission of education, empowerment and equal access to medicine for everyone affected by diabetes. Collaborating with governments, healthcare professionals, diabetes experts and individuals living with diabetes around the world, the Team Type 1 Foundation is bridging the ...

Diabetes Hands Foundation

TuDiabetes.org was co-founded in 2007 by Manny Hernandez, a diabetes advocate and social media expert diagnosed with type 1 diabetes in 2002. The community is run by the Diabetes Hands Foundation, a 501c3 nonprofit that connects people touched by diabetes and raises diabetes awareness.

GI Dynamics

GI Dynamics is focused on developing effective, non-surgical approaches for treating type 2 diabetes and obesity. The company’s patented EndoBarrier™ Technology has the potential to deliver medical interventions for patients combating weight problems and diabetes or diabetes risk factors. Data from clinical trials demonstrate that the EndoBarr...

The T1D Exchange

The T1D Exchange is a unique platform for collaborative data collection and sharing that consists of three overlapping components: a clinic-based registry with clinical, biological and other real-life information from individuals with type 1 diabetes, a registry that is coordinated through a network of clinical centers and an interactive online community f...

Avid Radiopharmaceuticals, Inc.

Avid Radiopharmaceuticals is a leader in the development of molecular imaging products with the potential for earlier and more effective detection, diagnosis and monitoring of major chronic human diseases. Based in Philadelphia, PA, the company’s lead program is a molecular imaging agent for amyloid plaque that could lead to earlier detection and bett...

MannKind

MannKind is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, Technosphere® Insulin System, is currently in phase 3 clinical trials in the U.S. and Europe to study its safety and efficacy in the treatment of diabetes. This therapy consists of a propri...

T1D Exchange

T1D Exchange was founded on the belief that people affected by type 1 diabetes need better solutions faster – better treatments and better care. Our nonprofit organization takes an innovative approach that puts the community of people touched by type 1 diabetes at the center of research that will meaningfully impact their lives. Our integrated model ...

Team Type 1

Based in Atlanta, GA, Team Type 1 began as a grassroots initiative to motivate people to take control of their diabetes using cycling as a platform. It grew to become a world-class athletic program for all athletes with diabetes, including a professional men's cycling team, poised to compete at the 2012 Tour de France. Today, it is a global sports organiza...

Betalin Therapeutics Ltd.

Pancreatic islet transplantation is currently performed in certain patients with Type 1 diabetes whose blood glucose levels are difficult to control. Pancreatic islet transplantation is a procedure in which islets, containing beta cells, from the pancreas of a deceased organ donor are purified, processed, and transferred into another person. Transplant ...

GlycoMark, Inc.

GlycoMark is an FDA-cleared blood test that reveals repeated episodes of postprandial hyperglycemia/glycemic variability by tracking postprandial glucose levels as they related to blood levels of the molecule 1,5-anhydroglucitol (1,5-AG). Multiple published studies indicate that 1,5-AG detects hyperglycemia not detected by the hemoglobin A1C test. A recent study conducted as part of the internat...

Bristol-Myers Squibb Company

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

Bristol-Myers Squibb Company & AstraZeneca

Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for type 2 diabetes. The Bristol-Myers Squibb/AstraZeneca Diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treat...

Bristol-Myers Squibb Company and AstraZeneca

Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for type 2 diabetes. The Bristol-Myers Squibb/AstraZeneca Diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treat...

Bristol-Myers Squibb and AstraZeneca

Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for type 2 diabetes. The Bristol-Myers Squibb/AstraZeneca Diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treat...


More From BioPortfolio on "A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks